Warning letter
Laboratorios Jaloma S.A. de C.V.: warning letter of May 22, 2026
FDA warning letter 725939 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 725939 |
|---|---|
| Company | Laboratorios Jaloma S.A. de C.V. |
| Subject | CGMP/OTC/Finished Pharmaceuticals/Adulterated |
| Issue date | May 22, 2026 |
| Posted date | Jun 2, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 211.22, 211.34, 211.68(b), 211.160(b), 211.194(a) |
| Inspection city | Guadalajara |
| Inspection start date | Dec 15, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: